Smoking, older age put patients receiving tofacitinib at higher risk for MACE vs. TNFi

Patients aged 65 years and older or who have ever smoked are at higher risk for malignancies, major adverse cardiovascular events, myocardial infarction and all-cause death when using tofacitinib vs. TNF inhibitors, according to data. Meanwhile, patients aged younger than 65 years who have never smoked demonstrated no apparent increased risk when receiving tofacitinib (Xeljanz, Pfizer), compared

Related Keywords

Denmark ,Frederiksberg ,Nordjylland ,Copenhagen ,Køavn ,Bispebjerg ,Hovedstaden ,United States ,Netherlands ,America ,Dutch ,Lars Erik Kristensen ,Amgen ,Parker Institute ,Pfizer ,Ann Rheum Dis ,Erik Kristensen ,Frederiksberg Hospital ,North America ,